Market cap
₹95,803 Cr
Recently Viewed
Clear AllNSE: MANKIND | BSE: 543904
₹2,338.80
₹19.30
(0.83%)
As on 06-May-2026 11:24IST
Market cap
₹95,803 Cr
Revenue (TTM)
₹13,914 Cr
P/E Ratio
53.8
P/B Ratio
6.1
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹1,779 Cr
ROE
17 %
ROCE
18.3 %
Industry P/E
30.43
EV/EBITDA
26.8
Debt to Equity
0.6
Book Value
₹380.2
EPS
₹45.3
Face value
1
Shares outstanding
412,828,328
CFO
₹10,889.22 Cr
EBITDA
₹16,050.64 Cr
Net Profit
₹11,497.60 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Mankind Pharma
| 6.5 | 17.0 | 12.4 | -3.2 | -- | -- | -- |
|
BSE Healthcare
| 6.0 | 11.3 | 9.2 | 8.7 | 25.8 | 13.9 | 11.5 |
|
Company
|
2025
|
2024
|
|---|---|---|
|
Mankind Pharma
| -23.8 | 45.5 |
|
BSE Mid Cap
| 1.1 | 25.8 |
|
BSE Healthcare
| -3.3 | 43.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Mankind Pharma
|
2,338.8 | 95,803.0 | 13,914.1 | 1,792.3 | 17.8 | 12.6 | 53.8 | 6.1 |
| 25,675.0 | 53,810.7 | 6,824.1 | 1,524.1 | 25.9 | 37 | 35.3 | 12.3 | |
| 5,614.0 | 64,627.3 | 14,252.7 | 2,424.5 | 17.5 | 19 | 27.3 | 4.6 | |
| 1,470.5 | 82,950.1 | 33,181.9 | 3,513.2 | 15.4 | 10.4 | 23.8 | 2.3 | |
| 382.4 | 59,795.3 | 16,827.4 | 629.6 | 9.6 | -0.1 | 99 | 1.6 | |
| 2,435.9 | 40,017.9 | 3,800.7 | 1,021.0 | 32.2 | 55 | 39.2 | 20.0 | |
| 1,566.7 | 39,170.7 | 9,504.5 | 947.8 | 15.9 | 14.6 | 43.1 | 5.0 | |
| 2,418.5 | 1,07,144.0 | 26,150.5 | 4,669.2 | 24.2 | 27 | 23.1 | 5.1 | |
| 1,840.8 | 4,36,858.9 | 56,809.1 | 11,001.4 | 23.9 | 16.2 | 40 | 5.4 | |
| 930.2 | 91,753.5 | 26,089.3 | 4,933.9 | 24.7 | 21 | 18.6 | 3.5 |
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products primarily in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of... anti-infective, cardiovascular, gastrointestinal, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, and respiratory diseases. It provides consumer healthcare products, such as condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. The company offers its products primarily under the Manforce, Prega News, Unwanted-72, Gas-O-Fas, Health OK, and AcneStar brand names. In addition, it engages in the trading and exporting of pharmaceutical and health care products; manufacturing of packing materials ayurvedic products, packing materials, bulk drugs, and consumer goods; real estate, leasing, and hospitality businesses; and provision of IT services. The company was incorporated in 1991 and is based in New Delhi, India. Read more
Incorporated
1991
Chairman
Ramesh Juneja
Managing Director
Rajeev Juneja
Headquarters
New Delhi, Delhi
Website
Looking for more details about Mankind Pharma Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsClarification sought from Mankind Pharma Ltd
27-Feb-2026No News & Announcements are available.
The share price of Mankind Pharma Ltd is ₹2,338.80 (NSE) and ₹2,338.30 (BSE) as of 06-May-2026 11:24 IST. Mankind Pharma Ltd has given a return of -3.17% in the last 1 years.
The P/E ratio of Mankind Pharma Ltd is 53.84 times as on 05-May-2026, a 77 premium to its peers’ median range of 30.43 times.
The P/B ratio of Mankind Pharma Ltd is 6.10 times as on 05-May-2026, a 32 premium to its peers’ median range of 4.62 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
50.22
|
7.00
|
|
2024
|
48.11
|
9.85
|
|
2023
|
0.00
|
0.00
|
|
2022
|
0.00
|
0.00
|
|
2021
|
0.00
|
0.00
|
The 52-week high and low of Mankind Pharma Ltd are Rs 2,716.50 and Rs 1,909.70 as of 06-May-2026.
Mankind Pharma Ltd has a market capitalisation of ₹ 95,803 Cr as on 05-May-2026. As per SEBI classification, it is a Mid Cap company.
Before investing in Mankind Pharma Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.